Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome: A randomised, placebo controlled, parallel group, multi-centre, multi-national trial with a 16-week double-blind period and 36- week open-label period (NN8022-4179)
Description
Study visits will be in downtown Buffalo
Objective This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.
Principal Investigator BETHIN, KATHLEEN
Age Group Children
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02527200/
Status Open
Key Eligibility Overweight children/adolescents
Ages 6-17
Prader-Willi Syndrome
Disease Group Children's Health/Pediatrics; Genetic Disorders; Obesity/Weight Loss
Treatment Liraglutide (Saxenda)
Contact BARBARA SHINE
716-878-7588
bjshine@buffalo.edu